The Poseidon study was a phase I/II study in second-line KRAS mild-type metastatic colorectal cancer (mCRC) that did not meet its endpoint of progression-free survival, but did suggest a subgroup of patients with high alpha v beta 6 integrin expression who would benefit from abituzumab. In this interview, Dr Rita Laeufle tells us about the retrospective analysis of the Poseidon study, whereby patients with left-sided KRAS wild-type mCRC and high expression of alpha v beta 6 showed improved overall survival and progression-free survival. Dr Laeufle explains how future research will start to focus on first-line therapy and how patients with other types of colon cancer can benefit from these results.
Questions:
1. What was the background and rationale behind the retrospective explorative analysis of the Poseidon study? (0:11)
2. What were the key findings from the analysis? (2:49)
3. What are the next steps in this area of research over the coming years? (3:27)
4. How do you anticipate these findings will impact clinical practice in the future? (4:33)
Speaker disclosures: Rita Laeufle has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
